GSK plc
GLAXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $55 | $60 | $58 | $65 |
| - Cash | $4 | $3 | $4 | $4 |
| + Debt | $17 | $18 | $21 | $24 |
| Enterprise Value | $68 | $75 | $75 | $85 |
| Revenue | $31 | $30 | $29 | $34 |
| % Growth | 3.5% | 3.4% | -14% | – |
| Gross Profit | $22 | $22 | $20 | $23 |
| % Margin | 71.2% | 71.8% | 67.4% | 66% |
| EBITDA | $7 | $9 | $9 | $6 |
| % Margin | 21.3% | 29.9% | 29.3% | 19% |
| Net Income | $3 | $5 | $15 | $4 |
| % Margin | 8.2% | 16.2% | 51% | 12.9% |
| EPS Diluted | 0.62 | 1.2 | 3.66 | 1.35 |
| % Growth | -48.3% | -67.2% | 171.1% | – |
| Operating Cash Flow | $7 | $7 | $7 | $8 |
| Capital Expenditures | -$3 | -$2 | -$2 | -$3 |
| Free Cash Flow | $4 | $4 | $5 | $5 |